The results may be compelling enough to get insurance companies to provide coverage, said Dr. Shauna Levy, a specialist in obesity medicine and the medical director of the Tulane Bariatric Center in New Orleans.
“Twenty percent is huge,” Levy said. “All of this narrative about people just wanting this for cosmetic reasons, I think, to some degree, has overshadowed all of the health benefits we can get from this medication.”The findings were based on a late-stage clinical trial of more than 17,000 adults ages 45 and up who got a 2.4-milligram dose of Wegovy or a placebo in addition to standard care.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen: